Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 1/20 | 0.56 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.50 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.48 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.47 |
| ▸ | BACE1 | P56817 | 2/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | MAOA | P21397 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 2/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3789234 | 0.87 | PTGS2 (0.50) | PTGS2FFAR4EPHX2BACE1CYP3A4 | |
| SCHEMBL4539011 | 0.85 | PTGS2 (0.62) | PTGS2FFAR4EPHX2BACE1TDP1 | |
| SCHEMBL3789813 | 0.82 | MAOA (0.53) | PTGS2FFAR4TAAR1BACE1CYP3A4 | |
| SCHEMBL5051426 | 0.82 | PTGS2 (0.56) | PTGS2FFAR4EPHX2TAAR1BACE1 | |
| SCHEMBL3789535 | 0.81 | CYP3A4 (0.42) | PTGS2FFAR4EPHX2TAAR1BACE1 | |
| SCHEMBL3781960 | 0.81 | TDP1 (0.50) | TAAR1CYP3A4TDP1HSD17B10MAOA | |
| SCHEMBL3786065 | 0.79 | TAAR1 (0.52) | TAAR1BACE1CYP3A4TDP1HSD17B10 | |
| SCHEMBL926391 | 0.79 | CYP3A4 (0.46) | PTGS2EPHX2BACE1CYP3A4TDP1 | |
| SCHEMBL30426786 | 0.79 | CYP3A4 (0.46) | PTGS2EPHX2BACE1CYP3A4TDP1 | |
| SCHEMBL3781383 | 0.79 | MAOA (0.48) | PTGS2EPHX2BACE1CYP3A4MAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100087680-A1 | METHOD FOR PRODUCING BIARYL COMPOUND | SUMITOMO CHEMICAL COMPANY LIMITED (JP) | 2010-04-08 | — | — | US | disclosed |
| EP-1914221-A1 | PROCESS FOR PRODUCING BIARYL COMPOUND | Sumitomo Chemical Company, Limited (JP) | 2008-04-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100087680-A1 | METHOD FOR PRODUCING BIARYL COMPOUND | NISCH, BLVRB, BBOX1 | PTGS2 3544/4885FFAR4 4051/4885EPHX2 701/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.